That is why BHS exists today…to provide an elite level of care your employees will not have access to unless provided by their employer. There is very slow (almost zero) adoption of these treatments in the healthcare system although it appears intuitive that a low cost and noninvasive option would benefit so many. Our results are simply amazing with 98% of employees reporting more than a 50% reduction in pain associated with their MSKs. 79% of MSKs are resolved without the need to go to a doctors’ office for another type of treatment. That is not just a huge savings in medical and/or workers’ compensation costs, but also time savings. The employer and office become the solution for the employees’ pains resulting in an overall higher quality of life and more productive employees. Williams, M. R. et al. The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr. Biol. 10, 439–448 (2000). To best understand costs and their key drivers it is important to explore how and by who those costs are incurred. MSK Costs to Employers:

of workplace injuries/illnesses are not treated by medical professionals, thus increasing the risk of further harm ( US National Library of Medicine National Institutes of Health (NIH)) Sapkota, G. P. et al. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem. J. 401, 29–38 (2007). Filipowska, J.; Tomaszewski, K.A.; Niedźwiedzki, Ł.; Walocha, J.A.; Niedźwiedzki, T. The role of vasculature in bone development, regeneration and proper systemic functioning. Angiogenesis 2017, 20, 291–302. [ Google Scholar] [ CrossRef][ Green Version] Ngo, L.; Knothe, L.E.; Knothe Tate, M.L. Knee Joint Tissues Effectively Separate Mixed Sized Molecules Delivered in a Single Bolus to the Heart. Sci. Rep. 2018, 8, 10254. [ Google Scholar] [ CrossRef] [ PubMed][ Green Version]Sutherland, C., Leighton, I. A. & Cohen, P. Inactivation of glycogen synthase kinase-3 β by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296, 15–19 (1993). Diehl, J. A., Cheng, M., Roussel, M. F. & Sherr, C. J. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499–3511 (1998). Richards, S. A., Fu, J., Romanelli, A., Shimamura, A. & Blenis, J. Ribosomal S6 kinase 1 (RSK1) activation requires signals dependent on and independent of the MAP kinase ERK. Curr. Biol. 9, 810–820 (1999). Nebreda, A. R. & Ferby, I. Regulation of the meiotic cell cycle in oocytes. Curr. Opin. Cell Biol 12, 666–675 (2000). Digital Solutions in MSK care are not new; however, have seen a great insurgence in market share due to the COVID-19 pandemic

Shahbazian, D. et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 25, 2781–2791 (2006). Iqbal, J.; Sun, L.; Zaidi, M. Denosumab for the treatment of osteoporosis. Curr. Osteoporos. Rep. 2010, 8, 163–167. [ Google Scholar] [ CrossRef]Raught, B. et al. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J. 23, 1761–1769 (2004). Ghoda, L., Lin, X. & Greene, W. C. The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IκBα and stimulates its degradation in vitro. J. Biol. Chem. 272, 21281–21288 (1997).